RESUMEN
Extracorporeal renal replacement therapy (ERRT) used in dogs with acute kidney injury (AKI) may be associated with hematological and hemostatic disorders. However, its characteristics are not fully described in dogs. The purpose of this pilot study was to characterize the impact of ERRT on hematological, hemostatic, and thromboelastometric parameters in dogs with AKI. We conducted a prospective observational single cohort study in 10 client-owned dogs with AKI associated leptospirosis undergoing ERRT. Results from the CBC, coagulation tests (prothrombin and activated partial thromboplastin times [aPTT]) and rotational thromboelastometry (TEM; intrinsic TEM [inTEM] and heparinase-based TEM [hepTEM]) were recorded before and after the first ERRT session. Blood abnormalities observed before the ERRT session included thrombocytopenia (10/10), anemia (8/10), leukocytosis (4/10), prolonged aPTT (4/10) and leukopenia (1/10). After ERRT, the platelet count decreased (-25%; Pâ¯=â¯.012) whereas leukocytes (+15%; Pâ¯=â¯.046) and aPTT (+24%; Pâ¯=â¯.006) increased. The clotting time (CT) on inTEM assay and the relative variation of CT based on inTEM and hepTEM profiles increased after the ERRT session (Pâ¯=â¯.037 and Pâ¯=â¯.048, respectively). Seven dogs, 2 dogs, and 1 dog were defined as having a normal, hypocoagulable, and hypercoagulable inTEM profile after ERRT, respectively. After ERRT, no hepTEM parameter was significantly different from before treatment. Platelet count, leukocytes, aPTT and CT were altered after the first ERRT session. Beyond the hemostatic abnormalities expected by the use of UFH, thrombocytopenia appears as the only hemostatic change after a single ERRT session in dogs with AKI.
Asunto(s)
Lesión Renal Aguda/veterinaria , Enfermedades de los Perros/terapia , Leptospirosis/veterinaria , Terapia de Reemplazo Renal/veterinaria , Lesión Renal Aguda/terapia , Animales , Recuento de Células Sanguíneas/veterinaria , Pruebas de Coagulación Sanguínea/veterinaria , Estudios de Cohortes , Enfermedades de los Perros/sangre , Enfermedades de los Perros/microbiología , Perros , Femenino , Leptospira/aislamiento & purificación , Leptospirosis/complicaciones , Masculino , Proyectos Piloto , Estudios Prospectivos , Terapia de Reemplazo Renal/efectos adversos , Tromboelastografía/veterinaria , Trombocitopenia/veterinaria , Resultado del TratamientoRESUMEN
OBJECTIVE: To determine the effect of Yunnan Baiyao (YB) on hemostatic parameters measured by thromboelastography (TEG) in apparently healthy cats administered 1 capsule of YB orally twice daily for 1 week. DESIGN: Prospective study of client-owned cats at a small animal specialty hospital. SETTING: One private referral center. ANIMALS: Twenty client-owned adult cats were prospectively enrolled. INTERVENTIONS: All cats underwent echocardiographic examination by the same board-certified cardiologist to rule out occult cardiomyopathy. Blood samples were collected for analysis of baseline CBC, fibrinogen, and kaolin-activated TEG values. Cats were administered 1 capsule (250 mg/capsule) of YB twice daily orally for 1 week and the physical examination, CBC, fibrinogen, and TEG were re-evaluated. Any side effects attributed to YB were noted at this time. MEASUREMENTS AND MAIN RESULTS: Three cats were excluded as 2 cats were identified with underlying cardiomyopathy and another cat had a cystic mass in the cranial mediastinum identified via echocardiography. Seventeen cats were treated with YB; however, 1 cat could not complete the study due to severe vomiting associated with YB administration. The remaining 16 cats completed the study, although 2 additional cats experienced transient vomiting. Yunnan Baiyao administration was associated with a significant decrease in HCT and red blood cell count, although no cat became anemic. None of the TEG parameters significantly changed compared to baseline after 1 week of YB therapy. CONCLUSIONS: The results of this study suggest YB at a dose of 1 capsule orally twice daily in cats fails to produce any significant change in hemostatic parameters as measured by TEG, although it did significantly reduce HCT and red blood cell count. Yunnan Baiyao was tolerated for most of the cats, although 3 of 17 (17.6%) cats experienced vomiting. Clinicians should be aware of these effects before considering the use of YB in cats.
Asunto(s)
Gatos/sangre , Medicamentos Herbarios Chinos/farmacología , Hemostasis/efectos de los fármacos , Hemostáticos/farmacología , Tromboelastografía/veterinaria , Administración Oral , Animales , Gatos/fisiología , China , Medicamentos Herbarios Chinos/administración & dosificación , Femenino , Fibrinógeno , Hemostáticos/administración & dosificación , Masculino , Estudios Prospectivos , Tromboelastografía/efectos de los fármacosRESUMEN
BACKGROUND: The chromogenic anti-Xa assay, the gold standard for monitoring the anti-Xa effect of rivaroxaban, is not available as a cage-side diagnostic test for use in a clinical setting. HYPOTHESIS/OBJECTIVES: To evaluate clinical modalities for measuring the anticoagulant effects of rivaroxaban using a point-of-care prothrombin time (PT) and thromboelastography (TEG). ANIMALS: Six healthy Beagle dogs. METHODS: Prospective, experimental study. Four different doses of rivaroxaban (0.5, 1, 2, and 4 mg/kg) were administered PO to dogs. Single PO and 3 consecutive dosing regimens also were assessed. Plasma rivaroxaban concentration was determined using a chromogenic anti-Xa assay, point-of-care PT, and TEG analysis with 4 activators (RapidTEG, 1 : 100 tissue factor [TF100], 1 : 3700 tissue factor [TF3700], and kaolin), and results were compared. Spearman correlation coefficients were calculated between ratios (peak to baseline PT; peak reaction time [R] of TEG to baseline [R] of TEG) and anti-Xa concentration. RESULTS: Anti-Xa concentration had a significant correlation with point-of-care PT (R = 0.82, P < .001) and RapidTEG-TEG, TF100-TEG, and TF3700-TEG (R = 0.76, P < .001; R = 0.82, P < .001; and R = 0.83, P < .001, respectively). CONCLUSIONS AND CLINICAL IMPORTANCE: Overall, a 1.5-1.9 × delay in PT and R values of TEG 3 hours after rivaroxaban administration is required to achieve therapeutic anti-Xa concentrations of rivaroxaban in canine plasma. The R values of TEG, specifically using tissue factors (RapidTEG, TF100, TF3700) and point-of-care PT for rivaroxaban can be used practically for therapeutic monitoring of rivaroxaban in dogs.
Asunto(s)
Inhibidores del Factor Xa/farmacología , Tiempo de Protrombina/veterinaria , Rivaroxabán/farmacología , Tromboelastografía/veterinaria , Animales , Perros/sangre , Inhibidores del Factor Xa/administración & dosificación , Inhibidores del Factor Xa/farmacocinética , Masculino , Estudios Prospectivos , Rivaroxabán/administración & dosificación , Rivaroxabán/farmacocinéticaRESUMEN
OBJECTIVE: To determine the effect of Yunnan Baiyao (YB) on hemostatic parameters measured by thromboelastography (TEG) in healthy dogs administered 1 capsule of YB orally twice daily for 1 week. DESIGN: Prospective study of client-owned dogs at a small animal specialty hospital. SETTING: Private referral center. ANIMALS: Eighteen client-owned adult dogs weighing at least 15 kg. INTERVENTIONS: Dogs had a baseline TEG performed and then each dog was administered 1 capsule of YB twice daily by mouth for 1 week and the TEG was reevaluated. Any side effects attributed to YB were noted at this time. MEASUREMENTS AND MAIN RESULTS: All 18 enrolled dogs completed the study. Dogs that received 1 capsule (250 mg/capsule) of YB orally twice daily had significantly increased G as well as A30 and A60 values. There was also a significantly decreased LY30 and LY60 values after 1 week. The YB appeared well tolerated as only one dog developed mild diarrhea. CONCLUSIONS: The results of this study suggest that YB at 1 capsule orally twice daily in healthy medium to large breed dogs increases the strength of the clot as measured by TEG and that YB was apparently well tolerated in the study population reported here. Larger prospective studies in different disease states are warranted to further evaluate these preliminary findings.
Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Hemostasis/efectos de los fármacos , Hemostáticos/farmacología , Administración Oral , Animales , Perros , Medicamentos Herbarios Chinos/administración & dosificación , Femenino , Hemostáticos/administración & dosificación , Masculino , Estudios Prospectivos , Valores de Referencia , Tromboelastografía/veterinariaRESUMEN
OBJECTIVE To determine effects of oral administration of Yunnan Baiyao on platelet activation, coagulation, and fibrinolysis in healthy horses. ANIMALS 12 healthy adult horses. PROCEDURES In a randomized blinded crossover study that included a 4-week washout period between treatments, horses were orally administered a paste containing Yunnan Baiyao (15 mg/kg) or placebo at 12-hour intervals for 3 days. Blood samples were collected before start of treatment (time 0) and at 24 and 72 hours for a CBC, measurement of fibrinogen concentration, coagulation screening tests, and a panel of assays to assess platelet activation (including ADP- and collagen-induced aggregation and closure times, flow-cytometric variables of platelet-leukocyte aggregates, platelet membrane P-selectin and phosphatidylserine expression, and microparticle release), von Willebrand factor (vWF) concentration, and cofactor activity. In addition, thrombelastography was used to evaluate fibrin formation in tissue factor-activated whole blood and plasma and to assess tissue plasminogen activator-induced plasma fibrinolysis. For each treatment, values obtained before and 72 hours after start of administration were compared by use of Wilcoxon signed rank tests. RESULTS Yunnan Baiyao treatment had no significant effect on any hemostatic variable, compared with results for the placebo treatment. CONCLUSIONS AND CLINICAL RELEVANCE Administration of Yunnan Baiyao at a dosage typically used in clinical practice had no effect on in vitro measures of platelet or vWF function and no enhancement of fibrin-clot formation or stability. Any hemostatic actions of Yunnan Baiyao may require higher dosages or result from cell-surface interactions at sites of vascular and tissue injury not examined in this study.
Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Hemostasis/efectos de los fármacos , Caballos , Animales , Coagulación Sanguínea/efectos de los fármacos , Plaquetas/metabolismo , China , Estudios Cruzados , Método Doble Ciego , Femenino , Fibrinógeno/metabolismo , Citometría de Flujo/veterinaria , Masculino , Selectina-P/metabolismo , Activación Plaquetaria/efectos de los fármacos , Tromboelastografía/veterinaria , Resultado del Tratamiento , Factor de von Willebrand/metabolismoRESUMEN
The objective of this study was to describe the results of thromboelastography platelet mapping (TEG-PM) carried out using 2 techniques in 20 healthy dogs. Maximum amplitudes (MA) generated by thrombin (MAthrombin), fibrin (MAfibrin), adenosine diphosphate (ADP) receptor activity (MAADP), and thromboxane A2 (TxA2) receptor activity (stimulated by arachidonic acid, MAAA) were recorded. Thromboelastography platelet mapping was carried out according to the manufacturer's guidelines (2-analyzer technique) and using a variation of this method employing only 1 analyzer (1-analyzer technique) on 2 separate blood samples obtained from each dog. Mean [± standard deviation (SD)] MA values for the 1-analyzer/2-analyzer techniques were: MAthrombin = 51.9 mm (± 7.1)/52.5 mm (± 8.0); MAfibrin = 20.7 mm (± 21.8)/23.0 mm (± 26.1); MAADP = 44.5 mm (± 15.6)/45.6 mm (± 17.0); and MAAA = 45.7 mm (± 11.6)/45.0 mm (± 15.4). Mean (± SD) percentage aggregation due to ADP receptor activity was 70.4% (± 32.8)/67.6% (± 33.7). Mean percentage aggregation due to TxA2 receptor activity was 77.3% (± 31.6)/78.1% (± 50.2). Results of TEG-PM were not significantly different for the 1-analyzer and 2-analyzer methods. High correlation was found between the 2 methods for MAfibrin [concordance correlation coefficient (r) = 0.930]; moderate correlation was found for MAthrombin (r = 0.70) and MAADP (r = 0.57); correlation between the 2 methods for MAAA was lower (r = 0.32). Thromboelastography platelet mapping (TEG-PM) should be further investigated to determine if it is a suitable method for measuring platelet dysfunction in dogs with thrombopathy.
Cette étude visait à décrire les résultats de la cartographie de la thromboélastographie des plaquettes (TEG-PM) effectuée à l'aide de deux techniques chez 20 chiens en santé. L'amplitude maximale (MA) générée par la thrombine (MAthrombine), la fibrine (MAfibrine), l'activité du récepteur de l'adénosine diphosphate (ADP) (MAADP), l'activité du récepteur de la thromboxane A2 (TxA2) (stimulée par l'acide arachidonique, MAAA) ont été mesurées. La TEG-PM a été effectuée selon les recommandations du manufacturier (technique à 2 analyseurs) ainsi qu'une variation de cette méthode en utilisant seulement un analyseur (technique à 1 analyseur) sur deux échantillons sanguins séparés obtenus de chaque chien. Les valeurs moyennes [± écart-type (SD)] de MA pour les techniques à 1 analyseur/2 analyseurs étaient: MAthrombine = 51,9 mm (± 7,1)/52,5 mm (± 8,0); MAfibrine = 20,7 mm (± 21,8)/23,0 mm (± 26,1); MAADP = 44,5 mm (± 15,6)/45,6 mm (± 17,0); et MAAA = 45,7 mm (± 11,6)/45,0 mm (± 15,4). La moyenne (± SD) du pourcentage d'agrégation due à l'activité du récepteur ADP était de 70,4 % (± 32,8)/67,6 % (± 33,7). La moyenne du pourcentage d'agrégation due à l'activité du récepteur TxA2 était de 77,3 % (± 31,6)/78,1 % (± 50,2). Il n'y avait pas de différence significative dans les résultats de TEG-PM entre les méthodes à 1 analyseur ou à 2 analyseurs. Une corrélation élevée a été trouvée entre les deux méthodes pour la MAfibrine [coefficient de concordance de corrélation (r) = 0,930]; une corrélation modérée a été trouvée pour MAthrombine (r = 0,70) et MAADP (r = 0,57); la corrélation entre les deux méthodes pour MAAA était plus faible (r = 0,32). Des études supplémentaires devraient être effectuées pour déterminer si la TEG-PM est une méthode qui convient pour mesurer le dysfonctionnement des plaquettes chez les chiens avec thrombopathie.(Traduit par Docteur Serge Messier).